Nuvation Bio
NUVB
124 hedge funds and large institutions have $250M invested in Nuvation Bio in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 38 reducing their positions, and 18 closing their positions.
10% more capital invested
Capital invested by funds: $228M → $250M (+$22M)
3% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 38
0.45% more ownership
Funds ownership: 63.12% → 63.58% (+0.45%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 129 → 124 (-5)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.79M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$1.87M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$731K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$634K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$582K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.43M |
| 2 |
6CM
683 Capital Management
New York
|
-$893K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$762K |
| 4 |
Millennium Management
New York
|
-$566K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$407K |
NUVB Hedge Fund Activity: Q2 2023 in Review
124 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q2 2023, worth a combined $250M — up 9.6% from $228M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of NUVB and 13 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 39 added.
The largest buyer was BlackRock, adding an estimated $3.79M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $2.43M sold.
- 124 institutional investors held Nuvation Bio (NUVB) as of Q2 2023, down from 129 in Q1 2023.
- Funds reported $250M of Nuvation Bio stock for Q2 2023, up 9.6% quarter-over-quarter.
- 13 funds opened new Nuvation Bio positions in Q2 2023 and 18 closed out, a net change of -5 holders.
- The largest Nuvation Bio buyer in Q2 2023 was BlackRock, an estimated $3.79M added.
- The largest Nuvation Bio seller in Q2 2023 was Farallon Capital Management, an estimated $2.43M sold.
Based on aggregated 13F filings for Q2 2023.